The Case of Zoom and Scaling Cloud Security

04/12/20 • 20 min

Zoom has not only experienced unprecedented, rapid growth (from 10M to 200M daily active users) due to the coronavirus pandemic and shelter-in-place -- but is also seeing a shift in use cases from primarily enterprise to more consumer as well. At the same time, there have been several security issues and concerns around Zoom, including "zoombombing" porn; home-grown encryption; and key-management systems, servers, and engineers in China.

The company had to correct and clarify the record as a result, but what does it mean to have enterprise-grade security How worried should we be (and who should worry) given that everyone from cycling classes and children's classes are now all online, many on Zoom or on related remote communication tools and applications? Especially now that healthcare providers (thanks to the U.S. Department of Health and Human Services Office of Civic Rights loosening up its enforcement of HIPAA regulations and related rules) are also serving patients "wherever they are during this national public health emergency”...

What's hype/what's real in the headlines here? In this episode of 16 Minutes, a16z general partner David Ulevitch (former SVP/GM at Cisco), and operating partner for security Joel de la Garza (former CSO of Box) break it all down in 16+ minutes with Sonal Chokshi. What does it all mean for related tech trends in bottom-up SaaS -- from user onboarding and the flip side of "earning the right to be complicated" to pricing & packaging -- as well as for open source; and cloud security, particularly when it comes to video?

Previous Episode

Drugs & Debates: Real World Data, Randomized Controlled Trials

If the best way to know whether a medicine is effective is through a clinical trial, then where does (and doesn't) real-world data and real-world evidence come in? The topic is always top of mind in drug development, with additional focus as of 2016 thanks to the 21st Century Cures Act -- but is especially heated lately given recent concerns and claims around particular drugs in the context of the novel coronavirus pandemic.

So in this short-but-deep dive episode of 16 Minutes on the News, a16z general partner in bio Vijay Pande -- previously a professor of Chemistry, Structural Biology, and Computer Science at Stanford University (as well as founder of Folding@Home) -- breaks down the debate between RWE vs. RCT (real world evidence and randomized controlled trials), in conversation with Sonal Chokshi. Is it a tradeoff between speed of innovation and safety, or is it a false dichotomy altogether? Where do and don't statistics come in when it comes to policy? How has, and could, the role of the FDA (as well as payers reimbursing healthcare) evolve here? And where can technology help?

Next Episode

CRISPR for Covid Testing and FDA EUAs

As calls for better, faster, cheaper, portable testing for COVID-19 disease are heard around the world -- given the important role of test-trace-isolate in re-opening the economy! -- the FDA recently issued an Emergency Use Authorization (EUA) for a CRISPR-based diagnostic.

It's the first authorized use of CRISPR technology for an infectious disease test. So we discuss this topic in this week's episode of 16 Minutes -- our show where we cover the news headlines, tease apart what's hype/what's real from our vantage point in tech, and share where we are on the overall arc of various trends -- covering:

where are we with testing for COVID overall given the taxonomy of what's already here and what's coming;
where are we with CRISPR technology, given that this is the one of the first times it's being used for diagnostics vs. therapeutics (and that clinical trials are only coming of age there now;
how does this work, and how does this type of CRISPR compare to the PCR approach for testing; and
how do EUAs and more play out given past policy debates and discussions of CRISPR and gene editing

...with a16z general partner Jorge Conde and bio deal team partner Andy Tran, in conversation with Sonal Chokshi.

On 16 Minutes, we also offer frameworks for thinking about the topics covered, so we also discuss: the tradeoffs between specificity and sensitivity when it comes to testing, especially when there's a big difference in false positives in testing for the disease vs. testing for antibodies; the tradeoffs between decentralized vs. centralized testing (getting the sample to the test or getting the test to the sample), especially given the potential for pregnancy-kit like tests here; and the tradeoffs between specific, scalable, and sensible testing ...Is it possible to have it all when it comes to CRISPR??